137 related articles for article (PubMed ID: 33022637)
21. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
22. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression.
Ma Y; Cang S; Li G; Su Y; Zhang H; Wang L; Yang J; Shi X; Qin G; Yuan H
J Cell Physiol; 2019 Dec; 234(12):22260-22271. PubMed ID: 31081124
[TBL] [Abstract][Full Text] [Related]
23. miR30a inhibits LOX expression and anaplastic thyroid cancer progression.
Boufraqech M; Nilubol N; Zhang L; Gara SK; Sadowski SM; Mehta A; He M; Davis S; Dreiling J; Copland JA; Smallridge RC; Quezado MM; Kebebew E
Cancer Res; 2015 Jan; 75(2):367-77. PubMed ID: 25488748
[TBL] [Abstract][Full Text] [Related]
24. Targeting ubiquitin-specific protease 22 suppresses growth and metastasis of anaplastic thyroid carcinoma.
Zhao HD; Tang HL; Liu NN; Zhao YL; Liu QQ; Zhu XS; Jia LT; Gao CF; Yang AG; Li JT
Oncotarget; 2016 May; 7(21):31191-203. PubMed ID: 27145278
[TBL] [Abstract][Full Text] [Related]
25. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2.
Cai F; Zhu Q; Miao Y; Shen S; Su X; Shi Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):59-69. PubMed ID: 27629878
[TBL] [Abstract][Full Text] [Related]
26. Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.
Lee SH; Kim JM; Lee DG; Lee J; Park JG; Han TS; Cho HS; Cho YL; Bae KH; Park YJ; Lee SJ; Lee MS; Huh YM; Jo DY; Yun HJ; Jeon HJ; Kim N; Joo M; Kim JS; Lee HJ; Min JK
Cell Death Differ; 2021 Mar; 28(3):968-984. PubMed ID: 32989241
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation.
Zhong Z; Hu Z; Jiang Y; Sun R; Chen X; Chu H; Zeng M; Sun C
Oncotarget; 2016 Sep; 7(37):59652-59663. PubMed ID: 27487122
[TBL] [Abstract][Full Text] [Related]
28. CTHRC1 promotes anaplastic thyroid cancer progression by upregulating the proliferation, migration, and invasion of tumor cells.
Chen Y; Jia L; Zhao K; Chen Z; Han Y; He X
PeerJ; 2023; 11():e15458. PubMed ID: 37273536
[TBL] [Abstract][Full Text] [Related]
29. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
30. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
31. ISG15 and ISGylation modulates cancer stem cell-like characteristics in promoting tumor growth of anaplastic thyroid carcinoma.
Xu T; Zhu C; Chen J; Song F; Ren X; Wang S; Yi X; Zhang Y; Zhang W; Hu Q; Qin H; Liu Y; Zhang S; Tan Z; Pan Z; Huang P; Ge M
J Exp Clin Cancer Res; 2023 Jul; 42(1):182. PubMed ID: 37501099
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
33. MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1.
Zhang W; Ji W; Zhao X
BMC Cancer; 2019 Nov; 19(1):1093. PubMed ID: 31718618
[TBL] [Abstract][Full Text] [Related]
34. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment.
Pan Z; Xu T; Bao L; Hu X; Jin T; Chen J; Chen J; Qian Y; Lu X; Li L; Zheng G; Zhang Y; Zou X; Song F; Zheng C; Jiang L; Wang J; Tan Z; Huang P; Ge M
Mol Cancer; 2022 Oct; 21(1):190. PubMed ID: 36192735
[TBL] [Abstract][Full Text] [Related]
35. EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF- Signals.
Hao F; Zhu Q; Lu L; Sun S; Huang Y; Zhang J; Liu Z; Miao Y; Jiao X; Chen D
Oncol Res; 2020 Sep; 28(4):345-355. PubMed ID: 32138807
[TBL] [Abstract][Full Text] [Related]
36. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
[TBL] [Abstract][Full Text] [Related]
37. TROP2 Down-regulated DSG2 to Promote Gastric Cancer Cell Invasion and Migration by EGFR/AKT and DSG2/PG/β-Catenin Pathways.
Yang T; Jia L; Bian S; Chang X; Zhang Q; Tang Q; Zhu J; Yang Z; Feng Z
Curr Cancer Drug Targets; 2022 Aug; 22(8):691-702. PubMed ID: 35392784
[TBL] [Abstract][Full Text] [Related]
38. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
39. c-Src/Cav1-dependent activation of the EGFR by Dsg2.
Overmiller AM; McGuinn KP; Roberts BJ; Cooper F; Brennan-Crispi DM; Deguchi T; Peltonen S; Wahl JK; Mahoney MG
Oncotarget; 2016 Jun; 7(25):37536-37555. PubMed ID: 26918609
[TBL] [Abstract][Full Text] [Related]
40. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
